Adhera Therapeutics Inc
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is… Read more
Adhera Therapeutics Inc (ATRX) - Net Assets
Latest net assets as of September 2023: $-26.32 Million USD
Based on the latest financial reports, Adhera Therapeutics Inc (ATRX) has net assets worth $-26.32 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.07K) and total liabilities ($26.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-26.32 Million |
| % of Total Assets | -59707.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | -858.05% |
| 10-Year Change | N/A |
| Growth Volatility | 3914.63 |
Adhera Therapeutics Inc - Net Assets Trend (1986–2022)
This chart illustrates how Adhera Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adhera Therapeutics Inc (1986–2022)
The table below shows the annual net assets of Adhera Therapeutics Inc from 1986 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-22.19 Million | +11.63% |
| 2021-12-31 | $-25.11 Million | -69.95% |
| 2020-12-31 | $-14.77 Million | -49.42% |
| 2019-12-31 | $-9.89 Million | -437.82% |
| 2018-12-31 | $2.93 Million | +552.93% |
| 2017-12-31 | $448.24K | -86.07% |
| 2016-12-31 | $3.22 Million | +1123.86% |
| 2015-12-31 | $263.00K | +106.02% |
| 2014-12-31 | $-4.37 Million | +38.12% |
| 2013-12-31 | $-7.06 Million | -18689.47% |
| 2012-12-31 | $38.00K | -99.78% |
| 2010-12-31 | $17.17 Million | +349.33% |
| 2009-12-31 | $-6.89 Million | -111.29% |
| 2008-12-31 | $-3.26 Million | -108.31% |
| 2007-12-31 | $39.22 Million | -9.50% |
| 2006-12-31 | $43.34 Million | -22.01% |
| 2005-12-31 | $55.57 Million | -4.44% |
| 2004-12-31 | $58.15 Million | +224.74% |
| 2003-12-31 | $17.91 Million | +107.13% |
| 2002-12-31 | $8.64 Million | -35.93% |
| 2001-12-31 | $13.49 Million | +41.08% |
| 2000-12-31 | $9.56 Million | -42.38% |
| 1999-12-31 | $16.60 Million | -34.90% |
| 1998-12-31 | $25.50 Million | +2.41% |
| 1997-12-31 | $24.90 Million | +111.02% |
| 1996-12-31 | $11.80 Million | +55.26% |
| 1994-12-31 | $7.60 Million | +76.74% |
| 1993-12-31 | $4.30 Million | +630.86% |
| 1992-12-31 | $-810.00K | +37.69% |
| 1991-12-31 | $-1.30 Million | -23.81% |
| 1990-12-31 | $-1.05 Million | -118.75% |
| 1989-12-31 | $-480.00K | -54.84% |
| 1988-12-31 | $-310.00K | -293.75% |
| 1987-12-31 | $160.00K | -62.79% |
| 1986-12-31 | $430.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adhera Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5255100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | % |
| Other Components | $33.55 Million | % |
| Total Equity | $-22.19 Million | 100.00% |
Adhera Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Adhera Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alumex PLC
CM:ALUMN0000
|
$669.83 |
|
Advanced Container Technologies Inc
PINK:ACTX
|
$670.31 |
|
Foothills S.A.
WAR:FTL
|
$670.51 |
|
Ampio Pharm
PINK:AMPE
|
$670.80 |
|
Patria Private Equity Trust
LSE:PPET
|
$669.32 |
|
BIG RED MINING CORP.
F:K8J
|
$668.41 |
|
Prism Technologies Group Inc
PINK:PRZM
|
$668.36 |
|
Meta Materials Inc.
NASDAQ:MMATQ
|
$667.37 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adhera Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -25,106,000 to -22,186,000, a change of 2,920,000.
- Net income of 2,352,000 contributed positively to equity growth.
- Dividend payments of 620,000 reduced retained earnings.
- Share repurchases of 2,000 reduced equity.
- Other factors increased equity by 1,190,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.35 Million | +10.6% |
| Dividends Paid | $620.00K | -2.79% |
| Share Repurchases | $2.00K | -0.01% |
| Other Changes | $1.19 Million | +5.36% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Adhera Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-12-31 | $0.03 | $0.00 | x |
| 1987-12-31 | $0.01 | $0.00 | x |
| 1988-12-31 | $-0.02 | $0.00 | x |
| 1989-12-31 | $-0.03 | $0.00 | x |
| 1990-12-31 | $-0.07 | $0.00 | x |
| 1991-12-31 | $-0.08 | $0.00 | x |
| 1992-12-31 | $-0.05 | $0.00 | x |
| 1993-12-31 | $11053.98 | $0.00 | x |
| 1994-12-31 | $15899.58 | $0.00 | x |
| 1996-12-31 | $789.56 | $0.00 | x |
| 1997-12-31 | $32634.34 | $0.00 | x |
| 1998-12-31 | $31994.98 | $0.00 | x |
| 1999-12-31 | $21474.77 | $0.00 | x |
| 2000-12-31 | $11213.36 | $0.00 | x |
| 2001-12-31 | $11179.78 | $0.00 | x |
| 2002-12-31 | $6899.44 | $0.00 | x |
| 2003-12-31 | $13098.76 | $0.00 | x |
| 2004-12-31 | $35916.00 | $0.00 | x |
| 2005-12-31 | $23756.73 | $0.00 | x |
| 2006-12-31 | $16340.87 | $0.00 | x |
| 2007-12-31 | $12554.42 | $0.00 | x |
| 2008-12-31 | $-882.96 | $0.00 | x |
| 2009-12-31 | $-1470.74 | $0.00 | x |
| 2010-12-31 | $1954.35 | $0.00 | x |
| 2012-12-31 | $1.20 | $0.00 | x |
| 2013-12-31 | $-0.42 | $0.00 | x |
| 2014-12-31 | $-35.49 | $0.00 | x |
| 2015-12-31 | $1.60 | $0.00 | x |
| 2016-12-31 | $13.57 | $0.00 | x |
| 2017-12-31 | $0.91 | $0.00 | x |
| 2018-12-31 | $5.40 | $0.00 | x |
| 2019-12-31 | $-18.24 | $0.00 | x |
| 2020-12-31 | $-27.16 | $0.00 | x |
| 2021-12-31 | $-38.61 | $0.00 | x |
| 2022-12-31 | $-9.61 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adhera Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2349.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | -232.56% | -169.49% | 0.74x | 1.86x | $-1.04 Million |
| 1987 | -629.41% | -297.22% | 0.75x | 2.82x | $-1.09 Million |
| 1988 | 0.00% | -100.00% | 0.97x | 0.00x | $-609.00K |
| 1989 | 0.00% | -30.25% | 1.53x | 0.00x | $-311.00K |
| 1990 | 0.00% | -59.21% | 1.12x | 0.00x | $-345.00K |
| 1991 | 0.00% | -96.88% | 0.65x | 0.00x | $-180.00K |
| 1992 | 0.00% | -11.63% | 1.15x | 0.00x | $-18.00K |
| 1993 | 4.65% | 9.52% | 0.35x | 1.40x | $-230.00K |
| 1994 | -1.32% | -3.45% | 0.31x | 1.24x | $-860.00K |
| 1997 | -18.07% | -109.76% | 0.15x | 1.10x | $-6.99 Million |
| 1998 | -3.53% | -11.11% | 0.29x | 1.08x | $-3.45 Million |
| 1999 | -50.60% | -186.67% | 0.22x | 1.22x | $-10.06 Million |
| 2000 | -101.32% | -234.03% | 0.36x | 1.22x | $-10.65 Million |
| 2001 | -68.42% | -354.67% | 0.17x | 1.14x | $-10.58 Million |
| 2002 | -155.79% | -150.94% | 0.39x | 2.67x | $-14.33 Million |
| 2003 | -11.96% | -11.01% | 0.62x | 1.74x | $-3.93 Million |
| 2004 | -49.20% | -1548.94% | 0.02x | 1.39x | $-34.42 Million |
| 2005 | -57.88% | -431.78% | 0.10x | 1.31x | $-37.72 Million |
| 2006 | -62.02% | -94.34% | 0.39x | 1.70x | $-31.21 Million |
| 2007 | -133.53% | -288.76% | 0.29x | 1.57x | $-56.29 Million |
| 2008 | 0.00% | -2269.84% | 0.20x | 0.00x | $-58.89 Million |
| 2009 | 0.00% | -54.62% | 2.04x | 0.00x | $-7.36 Million |
| 2010 | -161.65% | -1128.17% | 0.08x | 1.71x | $-29.47 Million |
| 2012 | -77431.58% | -1315.92% | 0.19x | 309.21x | $-29.43 Million |
| 2013 | 0.00% | -74.28% | 0.27x | 0.00x | $-864.60K |
| 2014 | 0.00% | -1295.40% | 0.05x | 0.00x | $-6.04 Million |
| 2015 | 1268.82% | 490.74% | 0.09x | 28.88x | $3.31 Million |
| 2016 | -26.00% | 0.00% | 0.00x | 1.92x | $-1.16 Million |
| 2017 | -1387.42% | 0.00% | 0.00x | 13.80x | $-6.26 Million |
| 2018 | -572.48% | -21992.23% | 0.01x | 1.76x | $-17.05 Million |
| 2019 | 0.00% | -4753.17% | 0.60x | 0.00x | $-10.99 Million |
| 2020 | 0.00% | -2853.03% | 132.00x | 0.00x | $-2.29 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.84 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $4.57 Million |
Industry Comparison
This section compares Adhera Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adhera Therapeutics Inc (ATRX) | $-26.32 Million | -232.56% | N/A | $669.77 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |